Damora Therapeutics Q2 2026: $31.2M Net Loss, $540.5M Cash, DMR-001 Phase 1/1b Underway
DMRA has more than doubled off its 52-week low of $2.45 on light trading volume (0.4× avg).
Summary
Damora Therapeutics reported a $31.2M net loss for Q2 2026, driven by a surge in R&D spending for its mutCALR pipeline. The company held $540.5M in cash, extending its runway into 2029, and disclosed the appointment of a new director and its redomestication to the Cayman Islands.
Key Events · Earnings and Guidance · DMRA
-
Q2 2026 Net Loss of $31.2M
Net loss widened to $31.2M from $3.4M in Q2 2025, driven by a $24.1M increase in R&D expenses to $25.5M as the company advanced DMR-001, DMR-002, and DMR-003.
-
Cash Runway Extended into 2029
Cash and equivalents stood at $540.5M as of June 30, 2026, following $295.5M in net proceeds from a February 2026 public offering and $29.3M from ATM sales. Management expects this to fund operations into the second half of 2029.
-
DMR-001 Phase 1/1b Trial Initiated
The company dosed the first patient in its Phase 1/1b CLARITY-101 trial of DMR-001, a long-acting antibody targeting mutant CALR, with proof-of-concept data expected beginning mid-2027.
-
New Director Appointed
Andrew Cheng, M.D., Ph.D., former CEO of Akero Therapeutics, was appointed as a Class III director effective August 12, 2026, bringing extensive biotech leadership experience.
Analysis · DMRA · Life Sciences
In its first quarterly report as a combined entity, Damora reveals a sharp ramp in spending to advance its mutCALR pipeline, with R&D expenses surging to $25.5M from $1.5M a year ago. The company ended the quarter with $540.5M in cash, providing runway into the second half of 2029. The filing also discloses the appointment of a new director and the completion of its redomestication to the Cayman Islands. While the loss is expected for a preclinical biotech, the scale of the cash burn and the early clinical progress for DMR-001 are the key takeaways for investors.
At the time of this filing, DMRA was trading at $29.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.45 to $38.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.